Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma

Authors: Y. N. Vashisht Gopal, Evelyn de Groot, Kaley Loftin, Barbara Knighton, Debora Ledesma, Courtney Hudgens, Diana Shamsutdinova, Mehboob Ali, Zhenlin Ju, Min Xiao, Toshitha Kannan, Gregory Fontenot, Michael S. Nakazawa, Monzy Thomas, Khalida Wani, Clifford Stephan, Phyu P. Aung, Lawrence N. Kwong, Janos Roszik, Rehan Akbani, Andrew Kossenkov, Vito W. Rebecca, Ryan J. Sullivan, Meenhard Herlyn, and Michael A. Davies

Nature Communications, 26 June 2026